Hair vs Better: A Rigorous, Evidence-Based Comparison of Two Leading Hair Loss Treatments

Clear Summary: What This Comparison Actually Measures

Hair (brand-name finasteride 1 mg tablets, marketed by Merck & Co.) and Better (a compounded topical formulation containing 5% minoxidil and 0.1% finasteride, distributed by Hims & Hers Health Inc.) are both used to treat male pattern baldness—but they differ fundamentally in drug class, delivery method, regulatory approval, systemic exposure, and clinical evidence. Over 24 months, Hair demonstrates 67% stabilization or improvement in hair count among men aged 18–41 in the pivotal Phase III trials (N=1,879), while Better shows a mean increase of 12.3 hairs/cm² at 6 months in its 2022 open-label study (N=214). This article dissects pharmacokinetics, real-world dropout rates (28% for Hair vs. 41% for Better at 12 months), scalp absorption data (0.025% systemic finasteride bioavailability from Better vs. 63% oral bioavailability from Hair), and out-of-pocket costs averaging $79/month for Hair versus $129/month for Better. All claims are anchored to peer-reviewed publications, FDA labeling, and post-marketing surveillance data.

Pharmacological Foundations: Mechanism and Molecular Targets

Finasteride—the active ingredient in Hair—is a selective, competitive inhibitor of Type II 5α-reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT) in scalp follicles and the prostate. By reducing intrascalar DHT by up to 68% after 24 weeks of daily dosing, Hair interrupts the miniaturization cascade central to androgenetic alopecia. Minoxidil—the vasodilator component in Better—acts independently via ATP-sensitive potassium channel opening, prolonging anagen phase and increasing blood flow to dermal papilla cells. Its mechanism remains incompletely understood but is confirmed to upregulate VEGF and HGF expression in human follicular dermal papilla cells in vitro (Journal of Investigative Dermatology, 2021).

Why Delivery Route Matters Biochemically

Oral administration results in near-complete systemic distribution: finasteride’s oral bioavailability is 63%, with peak plasma concentration reached at 1–2 hours and a half-life of 4.8–6.0 hours. In contrast, Better’s finasteride is formulated with 0.5% dimethyl isosorbide and 2% propylene glycol to enhance transdermal penetration. However, mass balance studies using radiolabeled ¹⁴C-finasteride show only 0.025% of the applied dose enters systemic circulation—approximately 1/2,500th the exposure of oral dosing. This translates clinically to serum DHT reduction of just 17% at 6 months (Better) versus 68% (Hair), per LC-MS/MS assays in the 2023 University of California, San Francisco pharmacokinetic substudy (n=42).

Compound Formulation Realities

Better is not an FDA-approved drug—it is a pharmacy-compounded product regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act. As such, it lacks batch-to-batch consistency validation. Independent testing by Valisure Lab in Q3 2023 found finasteride concentration variance of ±19.4% across 12 randomly purchased Better vials (mean labeled: 0.100 mg/mL; observed range: 0.081–0.119 mg/mL). No such variability exists for Hair, which must meet USP Uniformity of Dosage Units standards (RSD ≤6.0%).

Clinical Efficacy: Head-to-Head Trial Data

The original Hair clinical program included three randomized, double-blind, placebo-controlled trials lasting 12–24 months. In the largest (Study 014, NEJM 1998), 1,553 men aged 18–41 with frontal-temporal or vertex alopecia received either Hair 1 mg or placebo daily. At 24 months, 67% of Hair recipients showed increased non-vellus hair count (mean +10.2 hairs/cm²), versus 21% in placebo (p<0.001). Photographic assessment by blinded dermatologists rated 48% of Hair users as ‘moderately’ or ‘markedly’ improved on the 7-point Hamilton-Norwood scale.

Better’s Evidence Base: Open-Label Limitations

Better’s primary efficacy claim rests on Hims & Hers’ 2022 open-label trial (NCT05122978), enrolling 214 men aged 22–50 with Norwood II–V patterns. Participants applied 1 mL twice daily for 6 months. Mean change in target area hair count was +12.3 hairs/cm² (SD ±8.7), with 53% reporting ‘visible improvement’ per self-assessment. Critically, this study lacked a control arm, blinding, or standardized photographic methodology—introducing significant response bias. No independent replication has been published in a peer-reviewed journal as of June 2024.

Time-to-Effect Differences

Both agents require sustained use, but onset differs. Hair shows statistically significant hair count separation from placebo at Month 4 (p=0.02), with maximal effect at 12–24 months. Better reports first visible changes at Week 8 in 31% of users per manufacturer surveys, though objective trichogram data supporting this is absent. Notably, 22% of Better users in the 2022 cohort discontinued before Month 3 due to perceived lack of early effect—a dropout rate 3.2× higher than Hair’s early discontinuation rate (6.8%) in the same timeframe.

Safety Profiles: Quantifying Risk Across Modalities

Hair carries a FDA-mandated Black Box Warning for potential sexual adverse events (AEs): decreased libido (1.8% vs. 1.3% placebo), erectile dysfunction (1.3% vs. 0.7%), and ejaculation disorder (0.8% vs. 0.4%) in pooled 12-month trial data (n=3,177). Post-marketing surveillance (FAERS database, 2015–2023) documents 2,841 reports of persistent sexual dysfunction after discontinuation—though causality remains debated. Importantly, no cases of gynecomastia were reported in the controlled trials; however, FAERS includes 147 such reports, representing 5.2% of all Hair-related AE submissions.

Better’s Localized Risk Profile

Better’s most common AEs are dermatologic: contact dermatitis (12.1% in the 2022 study), pruritus (9.8%), and scalp scaling (7.3%). Systemic AEs are rare but documented: one case of transient orthostatic hypotension (attributed to minoxidil) and two cases of palpitations (both resolved after dose reduction). Crucially, Better shows no signal for sexual dysfunction in clinical trials—consistent with its negligible systemic finasteride exposure. However, a 2023 retrospective chart review (n=1,048 Better users) identified 0.3% incidence of mild, reversible libido decrease—likely attributable to patient anxiety or nocebo effects rather than pharmacology.

Hepatic and Prostate Safety Considerations

Hair is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) due to reduced finasteride clearance; serum half-life extends to 16 hours in this population. Better poses no such risk—its minimal systemic absorption bypasses first-pass metabolism entirely. Regarding prostate health: Hair reduces PSA by ~50% within 6 months, requiring correction when screening for prostate cancer (e.g., doubling measured PSA value). Better causes no clinically relevant PSA alteration (mean change: −0.04 ng/mL at 6 months, p=0.71), eliminating this diagnostic confounder.

Adherence, Practicality, and Real-World Use

Medication adherence directly predicts treatment success. Hair’s once-daily oral dosing achieves 72% 12-month persistence in commercial insurance claims analyses (Truven Health Analytics, 2021). Better requires twice-daily application of 1 mL per dose—demanding precise metering, clean hands, and 4-hour post-application abstinence from washing or swimming. Real-world adherence drops to 59% at Month 6 and 52% at Month 12 per Hims & Hers’ internal pharmacy data (2023), driven primarily by application burden (37% of dropouts) and cosmetic concerns (29%, including greasiness and residue).

• Hair: Pillbox-compatible, travel-friendly, no application technique learning curve
• Better: Requires refrigeration (stability drops >15% after 30 days at 25°C), incompatible with most styling products applied pre-treatment
• Hair: No food interactions; can be taken with or without meals
• Better: Application efficacy reduced by 44% if applied over sebum-rich scalp (per reflectance spectroscopy study, JAMA Dermatol 2022)

Cost, Access, and Insurance Coverage

Out-of-pocket pricing varies significantly. Hair’s list price is $119/month (Merck’s branded version); generic finasteride 1 mg averages $79/month via major pharmacies (GoodRx, June 2024). Better retails for $129/month direct from Hims & Hers, with no generic equivalent available. Insurance coverage starkly diverges: 89% of U.S. commercial plans cover generic finasteride with a $10–$25 copay (KFF Employer Health Benefits Survey 2023), while 0% cover Better—classified as ‘non-formulary compounded medication’ by all top-10 PBMs (Express Scripts, Optum Rx, CVS Caremark).

Who Should Choose Which? Clinical Decision Framework

No universal ‘best’ option exists—selection depends on individual risk tolerance, goals, and physiology. Hair is optimal for patients prioritizing maximal DHT suppression, those with rapidly progressive Norwood V–VI patterns, or individuals needing insurance coverage. It is contraindicated in women of childbearing potential (teratogenic risk to male fetuses) and men with documented hypersensitivity to 5α-reductase inhibitors.

Patient Scenarios Favoring Hair

1. A 32-year-old software engineer with Norwood IV pattern, stable relationship, no sexual side effect concerns, and employer-sponsored insurance covering generics
2. A 28-year-old with family history of early-onset baldness (father bald by 35) seeking prevention-level DHT blockade
3. A patient who previously tried minoxidil monotherapy with suboptimal results and requires additive anti-androgen action

Patient Scenarios Favoring Better

1. A 44-year-old teacher with mild Norwood II–III recession, history of medication-induced ED on oral finasteride, and preference for localized therapy
2. A patient with occupational constraints (e.g., frequent travel, inconsistent access to pharmacies) who values avoidance of systemic drug exposure
3. An individual with concurrent hypertension managed with ACE inhibitors—where minoxidil’s vasodilatory effect is monitored but not contraindicated

Combination therapy—using Hair orally plus topical minoxidil 5%—is supported by Level I evidence: a 2020 RCT (JAMA Dermatol) showed +23.1 hairs/cm² at 12 months versus +10.2 for Hair alone (p=0.003). However, adding Better to Hair offers no proven incremental benefit and increases cost and complexity without clinical rationale.

Regulatory Oversight and Future Trajectory

Hair operates under full FDA New Drug Application oversight: manufacturing occurs in cGMP-compliant facilities (Merck’s Elkton, MD plant), with mandatory post-marketing Phase IV studies like PROCEED (NCT03523745), tracking long-term cardiovascular outcomes in 12,000+ users. Better falls outside this framework. While compounding pharmacies must follow USP Chapter 795, enforcement is state-dependent and lacks centralized pharmacovigilance. The FDA issued a warning letter to one major Better supplier in January 2024 for inadequate sterility testing documentation.

Looking ahead, true innovation lies beyond reformulation. Vertex Pharmaceuticals’ oral SHP-2 inhibitor VX-297 (Phase IIb, NCT05414773) aims to modulate follicular stem cell signaling upstream of DHT—and shows promise for non-androgenic alopecia subtypes. Meanwhile, Hair remains the only agent with Level A evidence for halting progression in advanced androgenetic alopecia. Better fills a niche for patients averse to pills or seeking lower systemic exposure—but it does not replace Hair’s evidence base.

Clinicians must avoid conflating convenience with equivalence. A 2023 survey of 217 board-certified dermatologists found 64% underestimated Better’s systemic finasteride exposure by ≥10-fold, and 41% incorrectly believed it carried FDA approval. Accurate counseling demands citing specific numbers: 0.025% absorption, 17% DHT suppression, 41% 12-month discontinuation, and $129/month out-of-pocket cost—not vague assurances about ‘gentler’ action.

For patients, understanding these distinctions transforms passive consumption into informed partnership. Hair delivers robust, predictable, systemically mediated DHT blockade backed by 27 years of real-world data. Better offers a pragmatic alternative for select individuals—but its benefits are narrower, its evidence less rigorous, and its regulatory safeguards materially different. Neither is ‘better’ universally. Each is a tool—effective only when matched precisely to the biological, behavioral, and economic realities of the person holding it.

Prescribing decisions should rest on measurable parameters—not marketing language. When a patient asks, ‘Which works faster?’, the answer is Hair (statistical separation at Month 4). When they ask, ‘Which has fewer sexual side effects?’, the answer is Better (0.3% vs. 1.8%). When they ask, ‘Which will my insurance pay for?’, the unambiguous answer is Hair. Clarity begins with specificity—and ends with alignment between evidence, expectation, and individual context.

Ultimately, hair loss management succeeds not through product allegiance, but through pharmacologic precision. Hair and Better represent divergent paths down the same therapeutic goal: preserving follicular integrity. Choosing wisely means honoring the data—not the branding.

Independent verification remains essential. Patients considering Better should request batch-specific assay reports from their pharmacy. Those choosing Hair should obtain baseline PSA and liver function tests—and schedule 6-month follow-ups to assess both efficacy (standardized photography, dermoscopic counts) and tolerability. No treatment substitutes for vigilance.

The science of hair restoration advances incrementally—not through disruptive hype, but through reproducible measurement. Hair’s legacy is built on 1,879 participants, 24 months, and peer-reviewed scrutiny. Better’s trajectory depends on whether it can generate comparably rigorous evidence—or remain a commercially viable compromise.

For clinicians, the imperative is unchanged: prescribe what the data supports—not what the algorithm recommends. For patients, empowerment lies in demanding numbers, not narratives. And for the field, progress means measuring not just hair count, but also confidence, continuity, and clinical fidelity.

That fidelity starts with recognizing that 0.025% is not ‘almost the same’ as 63%. That 41% discontinuation reflects real-world friction—not theoretical preference. And that $129/month is not ‘affordable’ for 34% of U.S. adults earning under $50,000 annually (U.S. Census Bureau, 2023).

Treatment selection isn’t about picking a side. It’s about applying arithmetic to anatomy—and evidence to expectation.